"Totality-of-the-evidence" of proposed ustekinumab biosimilar SB17"

被引：0
|
作者：
Armuzzi, A. [1 ]
Girolomoni, G. [2 ]
Feldman, S. [3 ]
Goncalves, J. [4 ]
Park, Y. [5 ]
Ye, B. D. [6 ]
机构：
[1] IRCCS Humanitas Res Hosp, IBD Ctr, Milan, Italy
[2] Univ Verona, Dermatol, Verona, Italy
[3] Wake Forest Univ, Sch Med, Dermatol, Winston Salem, NC USA
[4] Univ Lisbon, Fac Pharm, Lisbon, Portugal
[5] Samsung Bioepis Co Ltd, Med Affairs, Incheon, South Korea
[6] Univ Ulsan, Coll Medicin, Gastroenterol Inflammatory Bowel Dis Ctr, Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1019
引用
收藏
页码：I1832 / I1834
页数：3
相关论文
共 50 条
  • [1] A TOTALITY-OF-THE-EVIDENCE APPROACH TO THE DEVELOPMENT OF GP2015, A PROPOSED ETANERCEPT BIOSIMILAR
    McCamish, M.
    DaSilva, A.
    Mayer, R. Ernst
    Fritsch, C.
    Schiestl, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1010 - 1010
  • [2] The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar
    Strand, Vibeke
    Girolomoni, Giampiero
    Schiestl, Martin
    Mayer, Robert Ernst
    Friccius-Quecke, Hilke
    McCamish, Mark
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (06) : 993 - 1003
  • [3] Characterization for the similarity assessment between proposed biosimilar SB17 and ustekinumab reference product using state-of-the-art analytical method
    Yang, S. Y.
    Lee, C.
    Hwang, K.
    Lee, J.
    Lee, J.
    Hong, J.
    Jung, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I424 - I424
  • [4] A Phase 1, Randomized, Double-Blind, Single-Dose Comparative Pharmacokinetic Study Comparing SB17 (Proposed Ustekinumab Biosimilar) with Reference Ustekinumab in Healthy Subjects
    Jeong, Hansol
    Kang, Taeseung
    Lee, Jiyoon
    Im, Seongsik
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB9 - AB9
  • [5] A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis
    Feldman, Steven R.
    Narbutt, Joanna
    Girolomoni, Giampiero
    Brzezicki, Jan
    Reznichenko, Nataliya
    Zegadlo-Mylik, Maria Agnieszka
    Pulka, Grazyna
    Dmowska-Stecewicz, Magdalena
    Klujszo, Elzbieta
    Rekalov, Dmytro
    Rajzer, Lidia
    Lee, Jiyoon
    Lee, Minkyung
    Rho, Young Hee
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (03) : 440 - 447
  • [6] SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation
    Peeters, Marc
    Lipp, Hans-Peter
    Park, Minjeong
    Yoon, Ye Chan
    Arnold, Dirk
    [J]. FUTURE ONCOLOGY, 2023, 19 (06) : 427 - 450
  • [7] Totality of the evidence at work: The first US biosimilar
    Holzmann, J.
    Balser, S.
    Windisch, J.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) : 137 - 142
  • [8] Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
    Selmaj, Krzysztof
    Roth, Karsten
    Hoefler, Josef
    Vitzithum, Klaus
    Derlacz, Rafal
    von Richter, Oliver
    Hornuss, Cyrill
    Poetzl, Johann
    Singer, Barry
    Jacobs, Laura
    [J]. BIODRUGS, 2024,
  • [9] The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
    Jerome Goldschmidt
    Vladimir Hanes
    [J]. Oncology and Therapy, 2021, 9 : 213 - 223
  • [10] The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product
    McClellan, Joseph E.
    Conlon, Hugh D.
    Bolt, Michael W.
    Katfayan, Vatche
    Palaparthy, Rameshraja
    Rehman, Muhammad, I
    Kirchhoff, Carol F.
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
12345